PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23963659-9	2013	This previously unrecognized long-term effect of sorafenib was mediated by AMPK-dependent inhibition of the mTORC1 pathway.	Sorafenib	49-58	CREB regulated transcription coactivator 1	Mus musculus	108-114	
23963659-10	2013	Suppression of mTORC1 activity was sufficient for sorafenib to hinder glucose utilization in breast cancer cells, as demonstrated by the observation that the mTORC1 inhibitor rapamycin induced a comparable down-regulation of GLUT-1 expression and glucose uptake.	Sorafenib	50-59	CREB regulated transcription coactivator 1	Mus musculus	15-21	
23963659-10	2013	Suppression of mTORC1 activity was sufficient for sorafenib to hinder glucose utilization in breast cancer cells, as demonstrated by the observation that the mTORC1 inhibitor rapamycin induced a comparable down-regulation of GLUT-1 expression and glucose uptake.	Sorafenib	50-59	CREB regulated transcription coactivator 1	Mus musculus	158-164	
23963659-11	2013	The key role of AMPK-dependent inhibition of mTORC1 in sorafenib mechanisms of action was confirmed by AMPKalpha1 silencing, which restored mTORC1 activity conferring a significant protection from cell death.	Sorafenib	55-64	CREB regulated transcription coactivator 1	Mus musculus	45-51	
23963659-11	2013	The key role of AMPK-dependent inhibition of mTORC1 in sorafenib mechanisms of action was confirmed by AMPKalpha1 silencing, which restored mTORC1 activity conferring a significant protection from cell death.	Sorafenib	55-64	CREB regulated transcription coactivator 1	Mus musculus	140-146